GlassScriptPhysician profile
Michael H Goldman
NPI 1437103892
$5,989.73
in general payments reported to CMS, 2019-2025
28 companies · $718 in 2025
The $718 reported for 2025 was more than what a typical Clinical & Laboratory Immunology (Internal Medicine) provider received nationally (typical 2025 total: $523).
See the full distribution for Clinical & Laboratory Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $99.91 · 2021: $93.77 · 2022: $215 · 2023: $276 · 2024: $4,484 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,440 · Food and Beverage: $1,687 · Travel and Lodging: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,440.00 |
| Food and Beverage | $1,687.19 |
| Travel and Lodging | $350.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4,455.09 | 2020-2025 | Xolair |
| Glaxosmithkline, LLC. | $221.83 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $164.92 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Genzyme Corporation | $156.27 | 2022-2025 | |
| Abbvie INC. | $132.42 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $111.25 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $101.99 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $87.62 | 2022-2024 | |
| Optinose US, INC. | $85.96 | 2019-2025 | |
| Pfizer INC. | $50.82 | 2021-2024 | |
| Blueprint Medicines Corporation | $44.53 | 2023-2024 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $34.90 | 2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.78 | 2022 | |
| Csl Behring | $27.30 | 2020 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $24.39 | 2023 | Auvi-Q |
| Leo Pharma INC. | $24.06 | 2025 | Anzupgo |
| Grifols USA, LLC | $23.80 | 2025 | Prolastin-C Liquid |
| Arcutis Biotherapeutics, INC. | $22.14 | 2025 | Zoryve |
| Pharming Healthcare, INC. | $21.82 | 2019 | |
| Incyte Corporation | $21.54 | 2025 | Opzelura |
| Amgen INC. | $21.41 | 2025 | Tezspire |
| Aytu Biopharma, INC. | $20.51 | 2024 | Karbinal |
| Seqirus USA INC | $19.05 | 2025 | Fluad, Flucelvax |
| Ionis Pharmaceuticals, INC. | $16.42 | 2025 | Dawnzera |
| Phadia US INC. | $13.42 | 2023 | Immunocap |
| Hikma Pharmaceuticals USA | $13.33 | 2024 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.